nach oben

Erschienen in:

28.12.2016 | Original Article

CD109, a negative regulator of TGF-β signaling, is a putative risk marker in diffuse large B-cell lymphoma

verfasst von: Maki Yokoyama, Masaaki Ichinoe, Sosei Okina, Yasutaka Sakurai, Norihiro Nakada, Nobuyuki Yanagisawa, Shi-Xu Jiang, Yoshiko Numata, Atsuko Umezawa, Koji Miyazaki, Masaaki Higashihara, Yoshiki Murakumo

Erschienen in: International Journal of Hematology | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

CD109 is a glycosylphosphatidylinositol-anchored glycoprotein that negatively regulates TGF-β signaling. CD109 was originally identified in hematopoietic tumors; however, the significance of CD109 in hematopoietic malignancies remains unclear. Here, we study the association of CD109 with diffuse large B-cell lymphoma (DLBCL) prognosis. Eighty-four DLBCL specimens were immunohistochemically analyzed for CD109 expression, and 31 and 53 cases were classified into low- and high-CD109 expression groups, respectively. CD109 expression was not associated with overall survival using the Kaplan–Meier analysis and log-rank tests (P = 0.17); however, a significant association was observed between high-CD109 expression and low-1-year survival (P = 0.01). Moreover, in combination with the revised International Prognostic Index (R-IPI), R-IPI-poor/CD109-high was associated with poorer prognosis compared with R-IPI-poor alone. We assessed TGF-β signaling in CD109-depleted Nalm6 cells (a human B-lymphoblastic leukemia/lymphoma cell line), and found prolonged Smad2 phosphorylation compared with control cells after TGF-β1 stimulation, suggesting that CD109 attenuates TGF-β1 signaling in human B-cell tumors. These results suggest that CD109 is a putative biomarker for identifying a high-risk group among DLBCL patients.

Brashem-Stein C, Nugent D, Bernstein ID. Characterization of an antigen expressed on activated human T cells and platelets. J Immunol. 1988;140:2330–3.PubMed

Sutherland DR, Yeo E, Ryan A, Mills GB, Bailey D, Baker MA. Identification of a cell-surface antigen associated with activated T lymphoblasts and activated platelets. Blood. 1991;77:84–93.PubMed

Lin M, Sutherland DR, Horsfall W, Totty N, Yeo E, Nayar R, et al. Cell surface antigen CD109 is a novel member of the α2 macroglobulin/C3, C4, C5 family of thioester-containing proteins. Blood. 2002;99:1683–91.CrossRefPubMed

Haregewoin A, Solomon K, Hom RC, Soman G, Bergelson JM, Bhan AK, et al. Cellular expression of a GPI-linked T cell activation protein. Cell Immunol. 1994;156:357–70.CrossRefPubMed

Murray LJ, Bruno E, Uchida N, Hoffman R, Nayar R, Yeo EL, et al. CD109 is expressed on a subpopulation of CD34⁺ cells enriched in hematopoietic stem and progenitor cells. Exp Hematol. 1999;27:1282–94.CrossRefPubMed

Smith JW, Hayward CP, Horsewood P, Warkentin TE, Denommme GA, Kelton J. Characterization and localization of the GOV^a/b alloantigens to the glycosylphosphatidylinositol-anchored protein CDwl09 on human platelets. Blood. 1995;86:2807–14.PubMed

Hashimoto M, Ichihara M, Watanabe T, Kawai K, Koshikawa K, Yuasa N, et al. Expression of CD109 in human cancer. Oncogene. 2004;23:3716–20.CrossRefPubMed

Sato T, Murakumo Y, Hagiwara S, Jijiwa M, Suzuki C, Yatabe Y, et al. High-level expression of CD109 is frequently detected in lung squamous cell carcinomas. Pathol Int. 2007;57:719–24.CrossRefPubMed

Hasegawa M, Moritani S, Murakumo Y, Sato T, Hagiwara S, Suzuki C, et al. CD109 expression in basal-like breast carcinoma. Pathol Int. 2008;58:288–94.CrossRefPubMed

10.

Hagiwara S, Murakumo Y, Sato T, Shigetomi T, Mitsudo K, Tohnai I, et al. Up-regulation of CD109 expression is associated with carcinogenesis of the squamous epithelium of the oral cavity. Cancer Sci. 2008;99:1916–23.CrossRefPubMed

11.

Hagikura M, Murakumo Y, Hasegawa M, Jijiwa M, Hagiwara S, Mii S, et al. Correlation of pathological grade and tumor stage of urothelial carcinomas with CD109 expression. Pathol Int. 2010;60:735–43.CrossRefPubMed

12.

Ohshima Y, Yajima I, Kumasaka MY, Yanagishita T, Watanabe D, Takahashi M, et al. CD109 expression levels in malignant melanoma. J Dermatol Sci. 2010;57:140–2.CrossRefPubMed

13.

Emori M, Tsukahara T, Murase M, Kano M, Murata K, Takahashi A, et al. High expression of CD109 antigen regulates the phenotype of cancer stem-like cells/cancer-initiating cells in the novel epithelioid sarcoma cell line ESX and is related to poor prognosis of soft tissue sarcoma. PLoS One. 2013;8:e84187.CrossRefPubMedPubMedCentral

14.

Tao J, Li H, Li Q, Yang Y. CD109 is a potential target for triple-negative breast cancer. Tumour Biol. 2014;35:12083–90.CrossRefPubMed

15.

Dong F, Wang Y, Li L, Wang Y, Liu X, Liu J. CD109 expression is increased in cutaneous squamous cell carcinoma. J Dermatol. 2014;41:947–9.CrossRefPubMed

16.

Finnson KW, Tam BY, Liu K, Marcoux A, Lepage P, Roy S, et al. Identification of CD109 as part of the TGF-β receptor system in human keratinocytes. Faseb J. 2006;20:1525–7.CrossRefPubMed

17.

Hagiwara S, Murakumo Y, Mii S, Shigetomi T, Yamamoto N, Furue H, et al. Processing of CD109 by furin and its role in the regulation of TGF-β signaling. Oncogene. 2010;29:2181–91.CrossRefPubMed

18.

Bizet AA, Liu K, Tran-Khanh N, Saksena A, Vorstenbosch J, Finnson KW, et al. The TGF-β co-receptor, CD109, promotes internalization and degradation of TGF-β receptors. Biochim Biophys Acta. 2011;1813:742–53.CrossRefPubMed

19.

Bizet AA, Tran-Khanh N, Saksena A, Liu K, Buschmann MD, Philip A. CD109-mediated degradation of TGF-β receptors and inhibition of TGF-β responses involve regulation of SMAD7 and Smurf2 localization and function. J Cell Biochem. 2012;113:238–46.CrossRefPubMed

20.

Litvinov IV, Bizet AA, Binamer Y, Jones DA, Sasseville D, Philip A. CD109 release from the cell surface in human keratinocytes regulates TGF-β receptor expression, TGF-β signaling and STAT3 activation: relevance to psoriasis. Exp Dermatol. 2011;20:627–32.CrossRefPubMed

21.

Zhang JM, Murakumo Y, Hagiwara S, Jiang P, Mii S, Kalyoncu E, et al. CD109 attenuates TGF-β1 signaling and enhances EGF signaling in SK-MG-1 human glioblastoma cells. Biochem Biophys Res Commun. 2015;459:252–8.CrossRefPubMed

22.

Sakakura H, Mii S, Hagiwara S, Kato T, Yamamoto N, Hibi H, et al. CD109 is a component of exosome secreted from cultured cells. Biochem Biophys Res Commun. 2016;469:816–22.CrossRefPubMed

23.

Li C, Hancock MA, Sehgal P, Zhou S, Reinhardt DP, Philip A. Soluble CD109 binds TGF-β and antagonizes TGF-β signaling and responses. Biochem J. 2016;473:537–47.CrossRefPubMed

24.

Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, et al. A revised European–American classification of lymphoid neoplasms: a proposal from the international Lymphoma Study Group. Blood. 1994;84:1361–92.PubMed

25.

De Paepe P, De Wolf-Peeters C. Diffuse large B-cell lymphoma: a heterogeneous group of non-Hodgkin lymphomas comprising several distinct clinicopathological entities. Leukemia. 2007;21:37–43.CrossRefPubMed

26.

Lossos IS. Molecular pathogenesis of diffuse large B-cell lymphoma. J Clin Oncol. 2005;23:6351–7.CrossRefPubMed

27.

Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Gilman P, et al. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 2001;19:389–97.CrossRefPubMed

28.

Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–42.CrossRefPubMed

29.

Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 2005;23:4117–26.CrossRefPubMed

30.

Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379–91.CrossRefPubMed

31.

Nyman H, Adde M, Karjalainen-Lindsberg ML, Taskinen M, Berglund M, Amini RM, et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood. 2007;109:4930–5.CrossRefPubMed

32.

The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329:987–94.

33.

Sehn LH, Berry B, Chhannabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109:1857–61.CrossRefPubMed

34.

Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by expression profiling. Nature. 2000;403:503–11.CrossRefPubMed

35.

Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fishear RI, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. N Engl J Med. 2002;346:1937–47.CrossRefPubMed

36.

Read JA, Koff JL, Nastoupil LJ, Williams JN, Cohen JB, Flowers CR. Evaluating cell-of origin subtype methods for predicting diffuse large B-cell lymphoma survival: a meta-analysis of gene expression profiling and immunohistochemistry algorithms. Clin Lymphoma Myeloma Leuk. 2014;14:460–7.CrossRefPubMedPubMedCentral

37.

Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275–82.CrossRefPubMed

38.

Castillo JJ, Bertran BE, Song MK, Ilic I, Leppa S, Nurmi H, et al. The Hans algorithm is not prognostic in patients with diffuse large B-cell lymphoma treated with R-CHOP. Leuk Res. 2012;36:413–7.CrossRefPubMed

39.

Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the committee on Hodgkin’s disease staging classification. Cancer Res. 1971;31:1860–1.PubMed

40.

Emori M, Tsukahara T, Murata K, Sugita S, Sonoda T, Kaya M, et al. Prognostic impact of CD109 expression in myxofibrosarcoma. J Surg Oncol. 2015;111:975–9.CrossRefPubMed

41.

Bierie B, Moses HL. Tumour microenvironment: TGFβ: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer. 2006;6:506–20.CrossRefPubMed

42.

Saltzman A, Munro R, Searfoss G, Franks C, Jaye M, Ivashchenko Y. Transforming growth factor-β-mediated apoptosis in the Ramos B-lymphoma cell line is accompanied by caspase activation and Bcl-XL downregulation. Exp Cell Res. 1998;242:244–54.CrossRefPubMed

43.

Spender LC, Inman GJ. TGF-β induces growth arrest in Burkett lymphoma cells via transcriptional repression of E2F-1. J Biol Chem. 2009;284:1435–42.CrossRefPubMed

44.

Kawabata KC, Ehata S, Komuro A, Takeuchi K, Miyazono K. TGF-β-induced apoptosis of B-cell lymphoma Ramos cells through reduction of MS4A1/CD20. Oncogene. 2013;32:2096–106.CrossRefPubMed

45.

Mao S, Yang W, Ai L, Li Z, Jin J. Transforming growth factor β type II receptor as a marker in diffuse large B cell lymphoma. Tumour Biol. 2015;36:9903–8.CrossRefPubMed

Titel: CD109, a negative regulator of TGF-β signaling, is a putative risk marker in diffuse large B-cell lymphoma
verfasst von: Maki Yokoyama
Masaaki Ichinoe
Sosei Okina
Yasutaka Sakurai
Norihiro Nakada
Nobuyuki Yanagisawa
Shi-Xu Jiang
Yoshiko Numata
Atsuko Umezawa
Koji Miyazaki
Masaaki Higashihara
Yoshiki Murakumo
Publikationsdatum: 28.12.2016
Verlag: Springer Japan
Erschienen in: International Journal of Hematology / Ausgabe 5/2017
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-016-2173-1

Springer Medizin

CD109, a negative regulator of TGF-β signaling, is a putative risk marker in diffuse large B-cell lymphoma

Abstract

Neu im Fachgebiet Onkologie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2017

Detection of chromosomal abnormalities by G-banding and prognostic impact in follicular lymphoma in the rituximab era

Primary cutaneous plasmacytoma

Regulation of normal and leukemic stem cells through cytokine signaling and the microenvironment

Refractory ITP in a patient with Kabuki syndrome: response to low-dose rituximab

Mouse immune thrombocytopenia is associated with Th1 bias and expression of activating Fcγ receptors

Body mass index is a prognostic factor in adult patients with acute myeloid leukemia

Neu im Fachgebiet Onkologie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Update Onkologie